Nobivac® Feline 1-HCP+FeLV

Feline Leukemia, Rhinotracheitis, Calici, Panleukopenia Vaccine, MODIFIED LIVE AND KILLED VIRUS

The only combination vaccine that provides 2-year duration of immunity1 for feline leukemia virus (FeLV) in addition to 1-year protection against feline rhinotracheitis, calicivirus, and panleukopenia.

Features and benefits

  • A quality core vaccine that protects against feline rhinotracheitis, feline panleukopenia virus (FPV), and feline calicivirus (FCV), in addition to providing extensive 2-year coverage for FeLV
  • Nobivac® Feline 1-HCP has been shown to block the replication of canine parvovirus (CPV) in cats1
    • Evidence shows that CPV-2a, CPV-2b, and CPV-2c isolates can replicate in cats, producing clinical signs of feline panleukopenia2-4
  • The only feline leukemia vaccine labeled to prevent persistent viremia for 2 years after vaccination5
  • Superior Efficacy demonstrated vs. multiple FeLV vaccines6,7
    • The ONLY USDA-licensed 2-Year Duration of immunity (DOI) FeLV vaccine1,5 (Ideal for adherence to AAFP guidelines8)
    • The ONLY vaccine to demonstrate efficacy over the long-term in a co-mingling study mimicking real life conditions1
  • Proven safety profile- 99% reaction-free in ongoing surveillance involving millions of doses1
  • The optimal choice for both indoor and outdoor cats of all ages and for all cats under 1 year of age


  • Approved for the vaccination of healthy cats as an aid in the prevention of disease caused by feline rhinotracheitis, calici, and panleukopenia viruses
  • Approved as an aid in the prevention of lymphoid tumors caused by, and diseases associated with feline leukemia virus (FeLV) infection
  • Vaccination with this product prevents persistent viremia in cats exposed to virulent FeLV
  • Recommended for use in healthy cats 9 weeks of age or older

Safety information

  • 98.8% reaction-free in field safety studies
  • 99.99% reaction-free in ongoing surveillance involving millions of doses1
  • Study showed no signs of inflammation or adjuvant at Day 21 after subcutaneous vaccination1
  • Two-year DOI means fewer vaccinations

Please see the product label for safety information.

Administration and Dosage

For cats 9 weeks of age or older:

  • Subcutaneous or intramuscular injection
  • Initial 1-mL dose administered at 9 weeks of age or older
  • Second 1-mL dose administered 3 to 4 weeks later
  • Revaccination every 2 years with 1 dose of Nobivac® Feline 1-HCP+FeLV is recommended
  • Revaccination in the intervening years with Nobivac® Feline 1-HCP is recommended

For further information, including complete directions and warnings, please see the product label.

Product label(s) and MSDS


  1. Data on file, Merck Animal Health.
  2. Hoelzer K, Parrish CR. The emergence of parvoviruses of carnivores. Vet Res. 2010;41(6):39.
  3. Ikeda Y, Nakamura K, Miyazawa T, Takahashi E, Mochizuki M. Feline host range of canine parvovirus: recent emergence of new antigenic types in cats. Emerg Infect Dis. 2002;8(4):341–346.
  4. Truyen U. Emergence and recent evolution of canine parvovirus. Vet Microbiol. 1999;69(1–2):47–50.
  5. Jirjis FF, Davis T, Lane J, et al. Protection against feline leukemia virus challenge for at least 2 years after vaccination with an inactivated feline leukemia virus vaccine. Vet Ther. 2010;11(2):E1–E6.
  6. Torres AN, O’Halloran KP, Larson LJ, Schultz RD, Hoover EA. Feline leukemia virus immunity induced by whole inactivated virus vaccination. Vet Immunol Immunopathol. 2010; 134 (1–2):122–131.
  7. Patel M, Carritt K, Lane J, Jayappa H, Stahl M, Bourgeois M. Comparative efficacy of feline leukemia virus inactivated whole virus vaccine and canarypox virus-vectored vaccine during virulent FeLV challenge and immunosuppression. Clin Vaccine Immunol. 2015.
  8. American Association of Feline Practitioners. AAFP 2013 feline vaccination advisory panel report. J Feline Med Surgery. 2013; 15:785-808.